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Salicylate Functions as an Efflux Pump Inducer and Promotes the
Emergence of Fluoroquinolone-Resistant Campylobacter jejuni Mutants
Abstract
Salicylate, a nonsteroidal anti-inflammatory compound, has been shown to increase the resistance of
Campylobacter to antimicrobials. However, the molecular mechanism underlying salicylate-induced
resistance has not yet been established. In this study, we determined how salicylate increases antibiotic
resistance and evaluated its impact on the development of fluoroquinolone-resistant Campylobacter mutants.
Transcriptional fusion assays, real-time quantitative reverse transcription-PCR (RT-PCR), and
immunoblotting assays consistently demonstrated the induction of the CmeABC multidrug efflux pump by
salicylate. Electrophoretic mobility shift assays further showed that salicylate inhibits the binding of CmeR (a
transcriptional repressor of the TetR family) to the promoter DNA of cmeABC, suggesting that salicylate
inhibits the function of CmeR. The presence of salicylate in the culture medium not only decreased the
susceptibility of Campylobacter to ciprofloxacin but also resulted in an approximately 70-fold increase in the
observed frequency of emergence of fluoroquinolone-resistant mutants under selection with ciprofloxacin.
Together, these results indicate that in Campylobacter, salicylate inhibits the binding of CmeR to the
promoter DNA and induces expression of cmeABC, resulting in decreased susceptibility to antibiotics and in
increased emergence of fluoroquinolone-resistant mutants under selection pressure.
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Salicylate, a nonsteroidal anti-inflammatory compound, has been shown to increase the resistance of
Campylobacter to antimicrobials. However, the molecular mechanism underlying salicylate-induced resistance
has not yet been established. In this study, we determined how salicylate increases antibiotic resistance and
evaluated its impact on the development of fluoroquinolone-resistant Campylobacter mutants. Transcriptional
fusion assays, real-time quantitative reverse transcription-PCR (RT-PCR), and immunoblotting assays con-
sistently demonstrated the induction of the CmeABC multidrug efflux pump by salicylate. Electrophoretic
mobility shift assays further showed that salicylate inhibits the binding of CmeR (a transcriptional repressor
of the TetR family) to the promoter DNA of cmeABC, suggesting that salicylate inhibits the function of CmeR.
The presence of salicylate in the culture medium not only decreased the susceptibility of Campylobacter to
ciprofloxacin but also resulted in an approximately 70-fold increase in the observed frequency of emergence of
fluoroquinolone-resistant mutants under selection with ciprofloxacin. Together, these results indicate that in
Campylobacter, salicylate inhibits the binding of CmeR to the promoter DNA and induces expression of
cmeABC, resulting in decreased susceptibility to antibiotics and in increased emergence of fluoroquinolone-
resistant mutants under selection pressure.
Sodium salicylates are commonly used as nonsteroidal anti-
inflammatory drugs (NSAIDs). The acetyl form of salicylate,
aspirin, is used widely in medicines and cosmetics. It has been
estimated that around 40,000 metric tons of aspirin are con-
sumed each year in the world (32). The main functions of
aspirin are to relieve minor aches and pains and to reduce
fever. Aspirin also has functions in decreasing the incidence of
strokes and heart attacks (3). Salicylic acid and salicylate are
the principal metabolites of aspirin (11). Sodium salicylate is
also used as an antipyretic, antiphlogistic, and analgesic agent
in livestock and poultry (12). In addition, salicylic acid is a
common compound in plants and in numerous foods and bev-
erages (13, 33). Therefore, salicylate is available to humans and
food-producing animals via multiple sources.
In addition to its effects in mammalian cells, salicylate also
alters the susceptibility of bacteria to antibiotics. Growth of
several bacterial species in the presence of salicylate induces
nonheritable resistance to multiple antibiotics (25). In Esche-
richia coli, the presence of salicylate increases resistance to
multiple antibiotics, including quinolones, cephalosporins, am-
picillin, nalidixic acid, tetracycline, and chloramphenicol (25,
27). Salicylate-induced multiple antibiotic resistance in E. coli
is mediated by increased transcription of the marRAB operon.
Salicylate inhibits the binding of the repressor protein MarR to
marO, the operator region of the mar operon, which then leads
to overexpression of the transcriptional activator protein
MarA (4). MarA modulates the transcription of a number of
genes, including decreased expression of OmpF (a porin) and
increased expression of the multidrug efflux pump AcrAB-
TolC, which results in multiple antibiotic resistance (2). In-
creased resistance to chloramphenicol and enoxacin in Salmo-
nella enterica serovar Typhimurium is also due to induction of
the mar regulon by salicylate (31). In Klebsiella pneumoniae,
salicylate-induced antibiotic resistance is due to increased ex-
pression of a MarA homologue, RamA, and the reduced pro-
duction of two porins (5, 7).
Campylobacter is recognized as a leading bacterial cause of
food-borne diseases in the United States and other developed
countries (30). According to a CDC report, campylobacteriosis
is estimated to affect over 0.84 million people every year in the
United States (29). Worldwide, Campylobacter infections ac-
count for 400 to 500 million cases of diarrhea each year (28).
Antibiotic treatment is recommended when the infection by
Campylobacter is severe or occurs in immunocompromised pa-
tients. However, Campylobacter has become increasingly resis-
tant to antimicrobials (18, 24). Among the known antibiotic
resistance mechanisms in Campylobacter, the CmeABC efflux
pump is an important player and confers resistance to struc-
turally diverse antibiotics and toxic compounds (17). It has
been demonstrated that CmeABC belongs to the RND family
of efflux transporters and is regulated by a transcriptional re-
pressor, CmeR, which binds to a specific site in the promoter
region of cmeABC (15, 17). Expression of CmeABC is induc-
ible by bile compounds, which interact with the ligand-binding
domain of CmeR and prevent binding of CmeR to the
cmeABC promoter in Campylobacter jejuni (14, 16). Further-
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more, it has been shown that overexpression of CmeABC in
Campylobacter significantly increases the frequency of emer-
gence of fluoroquinolone-resistant mutants (35).
Previously, it was shown that growth of Campylobacter in the
presence of salicylate resulted in a small but statistically sig-
nificant increase in resistance to ciprofloxacin, tetracycline, and
erythromycin (26). Later, Hannula and Hanninen confirmed a
salicylate-induced increase in resistance to ciprofloxacin in al-
most all examined Campylobacter strains (10). These studies
indicated that salicylate modulates Campylobacter resistance to
antibiotics, but how salicylate influences antibiotic resistance
and if it affects the emergence of antibiotic-resistant Campy-
lobacter mutants are unknown. Based on previous findings on
salicylate and cmeABC regulation, we hypothesized that salic-
ylate modulates antibiotic resistance in Campylobacter by al-
tering the expression of the CmeABC efflux pump. To examine
this hypothesis, we sought to compare the expression levels of
cmeABC with and without salicylate, to determine the interac-
tion of salicylate with the CmeR regulator, and to assess the
impact of salicylate on the emergence of fluoroquinolone-re-
sistant Campylobacter mutants.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains and plasmids used in
this study are listed in Table 1. C. jejuni strains were cultured on Mueller-Hinton
(MH) agar or in MH broth at 42°C microaerobically (5% O2, 10% CO2, and 85%
N2) in a gas incubator. C. jejuni strains with antimicrobial resistance markers
were grown on kanamycin (30 g/ml) or chloramphenicol (4 g/ml) when ap-
propriate. All strains were preserved as 30% glycerol stocks at 80°C.
Antimicrobial susceptibility tests. The MICs of antibiotics against C. jejuni
NCTC 11168 were determined using either Campylobacter MIC plates (Trek
Diagnostic Systems) or a broth microdilution method as described previously
(17). All assays were repeated at least three times.
Bacterial growth assays. Overnight cultures of C. jejuni NCTC 11168 were
diluted 100 times in fresh MH broth. Cultures were grown in 200-l volumes in
96-well plates and then supplemented with ciprofloxacin (0.125 g/ml), erythro-
mycin (0.125 g/ml), novobiocin (16 g/ml), or tetracycline (0.031 g/ml), alone
or together with salicylate (100 g/ml). The plate was incubated at 42°C for 20 h
in a microaerobic atmosphere, and the optical density at 600 nm was measured
by use of a FLUOstar Omega instrument (BMG Labtech, Offenburg, Germany).
-Galactosidase assay. To determine if salicylate induced the promoter activ-
ity of cmeABC, C. jejuni 11168 containing pABC11 (Table 1) was grown in MH
broth or MH broth supplemented with salicylate (100 g/ml) for 20 h, and the
cells were harvested to measure -galactosidase activity as described in a previ-
ous study (1). Since cj0561c is also regulated by CmeR (9), we further analyzed
the promoter activity of cj0561c in the presence of salicylate. The promoter
fusion construct for cj0561c was described by Guo et al. (9) and is listed in Table
1. All -galactosidase assays were repeated three times.
Real-time qRT-PCR. To further assess if the cmeABC operon is subject to
induction by salicylate, C. jejuni NCTC 11168 was cultured in MH broth, with or
without salicylate, for 20 h. The final concentrations of salicylate in the cultures
were 0, 100, and 200 g/ml. Total RNA was extracted from each of the cultures
by use of an RNeasy minikit (Qiagen, Valencia, CA) according to the protocol
supplied with the product and was further treated with a Turbo DNA-free kit
(Ambion, Austin, TX) to eliminate DNA contamination. Real-time quantitative
reverse transcription-PCR (qRT-PCR) analyses were conducted using an iScript
one-step RT-PCR kit with SYBR green (Bio-Rad) along with an MyiQ iCycler
real-time PCR detection system (Bio-Rad, Hercules, CA) as described previ-
ously (16). The primer sets used to detect the transcription levels of cmeB (9) and
cmeR (16) were described in previous publications. The 16S rRNA gene was used
for normalization. The qRT-PCR experiment was repeated three times, using
RNA samples prepared from three independent experiments.
SDS-PAGE and immunoblotting assay. In order to determine if salicylate
alters cmeABC expression at the protein level, C. jejuni 11168 was grown over-
night in MH broth containing 0, 100, or 200 g/ml of salicylate. Bacterial cells
were harvested from the cultures, and whole-cell proteins were analyzed by
SDS-PAGE and Western blotting, using anti-CmeA, anti-CmeB, anti-CmeC,
anti-Cj0561c, and anti-Momp antibodies as described previously (9, 17).
EMSA. To examine if salicylate inhibits CmeR binding to the promoter DNA
of cmeABC, an electrophoretic mobility shift assay (EMSA) was performed using
an EMSA kit (Invitrogen, Carlsbad, CA). Briefly, primers GSF and GSR1 (15)
were used to amplify the 170-bp promoter region of cmeABC. The purified PCR
products were incubated in 30-ng aliquots with 120 ng of purified recombinant
CmeR (rCmeR) carrying the C69S and C166S changes (15, 21) in 10 l of
binding buffer containing 250 mM KCl, 0.1 mM dithiothreitol, 0.1 mM EDTA,
and 10 mM Tris. The reaction mixtures were supplemented with salicylate (10
and 100 g), taurocholate (10 and 100 g), or ampicillin (10 and 100 g) and
then incubated for 20 min at room temperature. The reaction mixtures were then
subjected to electrophoresis on a nondenaturing 6% (wt/vol) polyacrylamide gel
in 0.5 TBE (44 mM Tris, 44 mM boric acid, 1 mM EDTA [pH 8.0]) at 200 V
for 45 min. The gel was stained in 1 TBE containing 1 SYBR gold nucleic
acid staining solution for 20 min. After washing of the gel in 150 ml of distilled
H2O for 10 s, the DNA bands were visualized under UV light at 254 nm.
Detection of spontaneous fluoroquinolone-resistant mutants. The emergence
of spontaneous fluoroquinolone-resistant Campylobacter mutants in the presence
or absence of salicylate was detected as described previously (35). Briefly, strain
NCTC 11168 was grown on MH agar plates for 20 h under microaerobic con-
ditions. The cells were collected and suspended in 1 ml MH broth. The total
CFU in the concentrated culture was determined by serial dilution and plating on
MH plates. Equal amounts of bacterial concentrate were plated onto salicylate-
free and salicylate-containing MH plates that contained three different concen-
trations of ciprofloxacin. The concentrations of ciprofloxacin used for enumer-
ating the mutants were 0.625, 1.25, and 4 g/ml, which are 5-, 10-, and 16-fold
higher, respectively, than the MIC for wild-type NCTC 11168. The frequency of
emergence of fluoroquinolone-resistant mutants was calculated as the ratio of
the CFU on ciprofloxacin-containing MH agar plates to the CFU of the inocu-
lated culture concentrate. This experiment was repeated three times. The sig-
nificance of differences in the frequencies of emergence of fluoroquinolone-
resistant mutants between salicylate-treated cultures and nontreated cultures was
determined by Student’s t test.
RESULTS
Salicylate increases Campylobacter resistance to several an-
tibiotics. To verify if salicylate affects the antimicrobial suscep-
tibility of Campylobacter, we measured the MICs of different
antibiotics in the absence and presence of salicylate (100 g/
ml). Growth of C. jejuni NCTC 11168 with salicylate resulted in
a moderate (2-fold) but reproducible increase in the MIC of
ciprofloxacin in multiple experiments. This result is consistent
with previous findings reported by others (10, 26). In this study,
salicylate did not affect the MICs of other examined antimi-
crobials, including azithromycin, gentamicin, florfenicol, nali-
dixic acid, clindamycin, rifampin, cefotaxime, and streptomy-
cin. However, the presence of salicylate increased the growth
rate of strain 11168 in the presence of various antibiotics,
including ciprofloxacin, erythromycin, novobiocin, and tetracy-
TABLE 1. Bacterial plasmids and strains used in this study
Bacterial strain or
plasmid Description or relevant genotype
Source or
reference
Plasmids
pMW10 Shuttle plasmid with promoterless lacZ 34
pABC11 pMW10 with the cmeABC promoter
sequence cloned in front of lacZ
1
pMW561 pMW10 with the promoter of cj0561c
inserted upstream of lacZ
9
C. jejuni strains
NCTC 11168 Wild-type C. jejuni 22
11168/pABC11 NCTC 11168 containing pABC11 1
W7/pMW561 11168W7 containing pMW561 9
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cline, at their corresponding MICs (Fig. 1). Together, these
results confirmed that salicylate decreased the susceptibility of
Campylobacter to antibiotics. It should be pointed out that the
enhanced resistance induced by salicylate was not inheritable.
After removing salicylate from the medium, the MIC of cip-
rofloxacin for strain 11168 returned to the baseline level (data
not shown).
Salicylate induces the expression of cmeABC in Campylo-
bacter. To determine if salicylate induces the expression of
cmeABC, we measured the -galactosidase activity of strain
11168/pABC11 grown in the presence or absence of salicylate.
Compared to the basal level of transcription in MH broth,
addition of salicylate (100 g/ml) to the culture resulted in a
3-fold increase in the expression of cmeABC (Fig. 2A). We
further examined the levels of the cmeB transcript in Campy-
lobacter cultures grown with different concentrations of salic-
ylate (0, 100, and 200 g/ml), using real-time qRT-PCR. As
shown in Fig. 2B, salicylate induced the transcription of cmeB
2- to 3-fold, in a dose-dependent manner. An immunoblotting
assay using anti-CmeABC antibodies further confirmed the
induction of CmeABC by salicylate (Fig. 3). According to
densitometric analysis (data not shown), the amounts of
CmeABC proteins increased 1.5- to 3-fold in the presence of
salicylate compared to the baseline control levels (in MH
broth). The major outer membrane protein (MOMP) band,
which was used as an internal control, did not show any
changes among the samples (Fig. 3). The protein data and the
transcriptional results all indicated that salicylate is an inducer
of CmeABC.
Since expression of CmeABC is controlled by CmeR (15),
we further determined if salicylate affected the transcription of
cmeR by using qRT-PCR. Results from three independent
experiments did not reveal any significant changes in the tran-
scription level of cmeR in the presence of salicylate (data not
shown), indicating that salicylate did not alter the expression of
cmeR. Thus, the enhanced expression of cmeABC by salicylate
is unlikely to be due to a change in cmeR transcription.
Salicylate interferes with CmeR binding to the cmeABC pro-
moter. Since salicylate induced expression of CmeABC but did
not alter the transcription of cmeR, we hypothesized that sa-
licylate might affect the function of CmeR by reducing its
affinity for the promoter DNA. To test this hypothesis, we
determined the effect of salicylate on the binding of CmeR to
the cmeABC promoter by using EMSA. The results showed
that salicylate produced a dose-dependent inhibition of CmeR
binding to the cmeABC promoter DNA (Fig. 4). Taurocholate
is a known inducer of cmeABC and was used as a control for
inhibition of CmeR binding. Although the inhibition by salic-
ylate was not as strong as that by taurocholate, the inhibitory
effect of salicylate on CmeR binding was clearly evident (Fig.
4). In contrast, ampicillin, which is not an inducer of cmeABC,
did not inhibit the binding of CmeR to the cmeABC promoter
DNA (Fig. 4).
Salicylate induces the expression of Cj0561c. In addition to
the control of cmeABC expression, CmeR also functions as a
repressor of Cj0561c (a putative periplasmic protein) in Cam-
FIG. 1. Effects of salicylate (100 g/ml) on the growth of C. jejuni
11168 in the presence of various antibiotics, including ciprofloxacin
(0.125 g/ml), erythromycin (0.125 g/ml), novobiocin (16 g/ml), and
tetracycline (0.031 g/ml). The bars represent the means and standard
deviations for triplicate samples from a single representative experi-
ment.
FIG. 2. Induction of the cmeABC operon in C. jejuni 11168 by
salicylate. (A) Transcriptional fusion (-galactosidase assay) demon-
strating the increased expression of cmeABC in the presence of salic-
ylate (100 g/ml). The bars represent the means and standard devia-
tions for triplicate samples from a single representative experiment.
(B) qRT-PCR results showing the increased transcript levels of cmeB
with salicylate (100 and 200 g/ml). Bacterial cells grown in MH broth
alone were used as the control for baseline expression. The bars rep-
resent the means and standard deviations for three independent ex-
periments.
FIG. 3. Immunoblotting analysis of CmeA, CmeB, CmeC, Cj0561c,
and MOMP production in NCTC 11168 grown with 0 (lanes 1, 4, and
7), 100 (lanes 2, 5, and 8), or 200 (lanes 3, 6, and 9) g/ml of salicylate.
Whole-cell proteins were used for immunoblotting with specific anti-
bodies against the indicated proteins. The position of each protein is
indicated by an arrow. MOMP was used as an internal control.
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pylobacter by specifically binding to the cj0561c promoter (9).
Since salicylate inhibited the function of CmeR, we suspected
that it might also induce the expression of Cj0561c in Campy-
lobacter. To examine this possibility, we evaluated the pro-
moter activity of cj0561c by using a transcriptional fusion con-
struct (pMW561) (Table 1). The -galactosidase activity of
strain W7/pMW561 grown in MH broth supplemented with
100 g/ml of salicylate increased 2.5-fold compared with
that for growth in MH broth without salicylate (Fig. 5). An
immunoblotting assay using anti-Cj0561c antibodies further
confirmed the induction of Cj0561c by salicylate (Fig. 3).
This induction result for Cj0561c is consistent with the result
that salicylate interferes with the function of CmeR in Cam-
pylobacter.
Salicylate increases the frequency of emergence of fluoro-
quinolone-resistant Campylobacter mutants. Since salicylate
induced the expression of CmeABC, we further examined if
the presence of salicylate modulates the emergence of fluoro-
quinolone-resistant Campylobacter. The results are shown in
Table 2. When 0.625 or 1.25 g/ml ciprofloxacin was used in
the selection plates for enumeration of mutants, C. jejuni 11168
exhibited similar frequencies of emergence of fluoroquin-
olone-resistant mutants, regardless of the presence of salicylate
in the growth medium (106; P  0.05). However, at a
ciprofloxacin concentration of 4 g/ml, incubation of strain
11168 with salicylate resulted in a 70-fold increase in the fre-
quency of emergence of ciprofloxacin-resistant mutants, and
the difference was statistically significant (P  0.05). These
findings indicate that salicylate increases the frequency of
emergence of fluoroquinolone-resistant mutants on plates with
a high concentration of ciprofloxacin.
DISCUSSION
The results from this study revealed that salicylate-mediated
decreases in the susceptibility of Campylobacter to antibiotics
are due at least partially to induction of expression of the
CmeABC efflux pump. This conclusion is based on multiple
pieces of experimental evidence derived from transcriptional
fusion assays (Fig. 2A), real-time qPCRs (Fig. 2B), and immu-
noblotting assays (Fig. 3). We further showed that salicylate
inhibits the binding of CmeR to its target promoters (Fig. 4),
leading to enhanced expression of CmeABC and Cj0561c in
the presence of salicylate (Fig. 2, 3, and 5). Together, these
results provide a molecular basis for salicylate-induced resis-
tance to antibiotics in Campylobacter.
The CmeABC efflux system plays an important role in re-
sistance to antibiotics and toxic compounds in Campylobacter
(17), and the expression of this efflux pump is modulated by
CmeR (15). Previous studies demonstrated that overexpres-
sion of CmeABC results in modest increases in the MICs of
antibiotics, including ciprofloxacin, erythromycin, novobiocin,
tetracycline, cefotaxime, and fusidic acid (15, 16). In this study,
we found that salicylate caused a small but reproducible in-
crease in the MIC of ciprofloxacin and facilitated the growth of
Campylobacter in the presence of inhibitory concentrations of
antibiotics (Fig. 1). This finding is consistent with the results
from previous studies using salicylate (10, 26).
CmeR is a pleiotropic regulator and functions as a transcrip-
tional repressor of cmeABC and cj0561c (9, 15). Cj0561c is a
periplasmic protein and is tightly controlled by CmeR due to
the presence of two CmeR-binding sites in the promoter se-
quence of Cj0561c (9). Although the exact function of Cj0561c
is unknown, a previous study showed that it contributes to the
in vivo fitness of Campylobacter in chickens (9). In this study,
we found that salicylate induced the expression of both
CmeABC and Cj0561c. This induction can be explained by the
fact that salicylate inhibited the binding of CmeR to promoter
DNA, as shown by EMSA (Fig. 4). Compared with that by bile
salts, which are strong inhibitors of CmeR binding (16), the
FIG. 4. Effects of salicylate, taurocholate, and ampicillin on the
formation of CmeR-DNA complexes as determined by EMSA. Each
reaction mixture contained 30 ng cmeABC promoter DNA and 120 ng
rCmeR (except for that in lane 1). The amounts of chemicals used in
the assay are indicated at the top.
TABLE 2. Frequencies of emergence of fluoroquinolone-resistant
C. jejuni mutants under different selection pressures
Ciprofloxacin
level (g/ml)
Frequency of mutant emergencea
No salicylate Salicylate (100 g/ml)
0.625 3.33  106  1.58  106 4.60  106  2.70  106
1.25 3.77  106  0.74  106 4.16  106  2.96  106
4 4.24  108  1.42  108 3.23  106  1.55  106*
a Data are means standard deviations for three independent experiments. ,
the difference from the no-salicylate control is statistically significant (P 0.024).
FIG. 5. Induction of cj0561c in C. jejuni 11168 by salicylate (100
g/ml), as determined by transcriptional fusion (-galactosidase as-
say). The bars represent the means and standard deviations for tripli-
cate samples from a single representative experiment.
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inhibition by salicylate was relatively weak but was visually
apparent (Fig. 4). This finding suggests that salicylate releases
the repression of CmeR on cmeABC and cj0561c, leading to
increased expression of the two genes.
Salicylate inhibits the function of CmeR, not the expression
level of this regulatory protein. This conclusion is based on the
fact that qRT-PCR did not detect altered transcription of
cmeR in the presence of salicylate (data not shown). How
salicylate modulates the function of CmeR is unclear at pres-
ent, but it is known that CmeR has a DNA-binding motif in the
N-terminal region and a flexible ligand-binding pocket in the
C-terminal region (8). It is possible that salicylate interacts
with the ligand-binding pocket and triggers a conformational
change in the DNA-binding domain, preventing CmeR binding
to promoter DNA. This possibility remains to be examined in
future studies. Based on results from this study and previously
known information on CmeR regulation, we present a model
that depicts the induction mechanisms of salicylate in Campy-
lobacter (Fig. 6). The binding of salicylate to CmeR appears to
be reversible, since removal of salicylate from the culture me-
dium restored cmeABC expression to the basal level (data not
shown).
Salicylate not only increases antibiotic resistance but also
promotes the emergence of spontaneous fluoroquinolone-re-
sistant Campylobacter mutants under selection pressure. In
Campylobacter, fluoroquinolone resistance is mediated by tar-
get modification (GyrA mutations) and by the efflux function
of CmeABC (6, 20, 23). A single point mutation in the quin-
olone resistance-determining region of gyrA DNA is sufficient
to significantly increase the resistance of Campylobacter to
fluoroquinolone antimicrobials (6, 18, 19, 24). A T86I substi-
tution in GyrA confers high-level resistance to fluoroquinol-
ones, while T86K, A70T, and D90N substitutions are associ-
ated with moderate resistance to fluoroquinolones (18, 24). It
is important that CmeABC functions synergistically with GyrA
mutations in conferring fluoroquinolone resistance and that
without CmeABC, GyrA mutants are unable to maintain the
resistance phenotype (18, 35). Thus, the expression level of
CmeABC affects the frequency of emergence of fluoroquin-
olone-resistant mutants in Campylobacter (35). In this study,
we showed that addition of salicylate to the culture medium
resulted in a 70-fold increase in the frequency of emergence of
ciprofloxacin-resistant mutants at a higher concentration of the
antibiotic (4 g/ml) (Table 2). This result is consistent with our
previous finding for a cmeR mutant in which CmeABC was
overexpressed, for which the frequency of emergence of fluo-
roquinolone-resistant mutants increased significantly (35).
For Campylobacter, it is known that different GyrA muta-
tions confer different levels of resistance, and the measured
frequencies of emergence of resistant mutants vary with the
concentration of ciprofloxacin in the plates (35). The presence
of salicylate in the medium did not alter the frequencies of
emergence of fluoroquinolone-resistant mutants (106)
when the concentrations of ciprofloxacin in the selection plates
were 5 times (0.625 g/ml) and 10 times (1.25 g/ml) higher
than the MIC (Table 2). This result can be explained by the
facts that the basal expression of CmeABC is sufficient and
that overexpression of this efflux pump is not required for
GyrA mutants to survive at low selection pressure (0.625 and
1.25 g/ml) (35). In contrast, with 4 g/ml of ciprofloxacin,
those GyrA mutants with lower MICs would require overex-
pression of cmeABC to survive the selection pressure, resulting
in a difference in the numbers of detected mutants with and
without salicylate. These results indicate that salicylate does
not affect the spontaneous mutation rate but facilitates the
emergence of fluoroquinolone-resistant mutants under antibi-
FIG. 6. Diagram depicting the molecular basis of salicylate-mediated induction of CmeABC and Cj0561c. (A) Baseline expression of the genes
in the absence of salicylate. Transcription of cmeABC and cj0561c is at a low level due to inhibition by CmeR. (B) Induction of the genes by
salicylate. When salicylate is present, it inhibits the binding of CmeR and ameliorates the repression on cmeABC and cj0561c, leading to
overexpression of CmeABC and Cj0561c.
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otic selection by inducing the expression of cmeABC. Similar
findings were obtained in a previous study in which mutation of
cmeR (overexpressed CmeABC) led to increased emergence of
ciprofloxacin-resistant mutants for selection with ciprofloxacin
at 4 g/ml but not at 0.625 and 1.25 g/ml (35).
In summary, this study identified the molecular mechanism
underlying salicylate-induced antibiotic resistance in Campylo-
bacter and revealed that salicylate promotes the emergence of
fluoroquinolone-resistant Campylobacter mutants under selec-
tion pressure. Although these findings were made under lab-
oratory conditions, they might be applicable to the ecological
niches occupied by C. jejuni under natural conditions. Consid-
ering the common presence of salicylate in plant and food as
well as its widespread use in veterinary and human medicine, it
is possible that C. jejuni is exposed to salicylate in animal
reservoirs and in the human host. Such exposure could con-
ceivably influence the development of antibiotic resistance in
this pathogenic organism. Those treating Campylobacter infec-
tions with fluoroquinolones should consider this possibility and
avoid the simultaneous use of salicylate-containing medicine or
salicylate-rich nutrients.
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